Li Zhang

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Systematic Review

Acute Lymphoblastic Leukemia

Decision Making

Multiple Myeloma

Top Venues

Cancer medicine

Clinical and experimental medicine

Hematology (Amsterdam, Netherlands)

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Wenjiao Tang, Yan Li, Li Zhang, Xushu Zhong, Qiushi Liang, Yuhuan Zheng, Yuzhang Liu, Yafei Wang, Xunqiang Wang, Yun Zeng, Baijun Fang, Li Zheng, Ting Niu
Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma. Cancer medicine 13 (14) (2024)
Xinyuan Gu, Wenjiao Tang, Li Zhang, Yuhuan Zheng, Ling Pan, Ting Niu
Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs. Clinical and experimental medicine 24 (1) (2024)
Yanqiu Xiong, Shan-Shan Liang, Wenjiao Tang, Li Zhang, Yuhuan Zheng, Ling Pan, Ting Niu
A predictive risk-scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South-Western China. Cancer medicine 13 (17) (2024)
Xinyuan Gu, Wenjiao Tang, Li Zhang, Yuhuan Zheng, Ling Pan, Ting Niu
Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs. Clinical and experimental medicine 24 (1) (2024)
Xinyuan Gu, Wenjiao Tang, Li Zhang, Yuhuan Zheng, Ling Pan, Ting Niu
Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs. Clinical and experimental medicine 24 (1) (2024)
Wenjiao Tang, Yan Li, Li Zhang, Xushu Zhong, Qiushi Liang, Yuhuan Zheng, Yuzhang Liu, Yafei Wang, Xunqiang Wang, Yun Zeng, Baijun Fang, Li Zheng, Ting Niu
Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma. Cancer medicine 13 (14) (2024)
Xinyuan Gu, Chunyan Sun, Juan Xu, Zhimei Lin, Li Zhang, Yuhuan Zheng
Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis. Hematology (Amsterdam, Netherlands) 28 (1) (2023)
Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhi-Ming Li, Yuqin Song, Li Zhang, Xiaojian Zhu, Huijing Wu, Wei Zhang, Junmin Li, Ke-Shu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zhenjiang Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: A phase 2, single-arm, open-label clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Wenjiao Tang, Yan Li, Zhongqing Zou, Jian Cui, Fangfang Wang, Yuhuan Zheng, Li Hou, Ling Pan, Bing Xiang, Hong Chang, Li Zhang, Ting Niu
A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma. Cancer medicine (2022)